Home » Stocks » Echo Therapeutics

Echo Therapeutics, Inc. (ECTE)

Stock Price: $0.0069 USD -0.0010 (-13.75%)
Updated Oct 23, 2020 9:30 AM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 80,288
Revenue (ttm) n/a
Net Income (ttm) -6.04M
Shares Out 11.64M
EPS (ttm) -1.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.0069
Previous Close $0.0080
Change ($) -0.0010
Change (%) -13.75%
Day's Open 0.0069
Day's Range 0.0069 - 0.0069
Day's Volume 0
52-Week Range 0.0029 - 0.015

More Stats

Market Cap 80,288
Enterprise Value 3.21M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.64M
Float n/a
EPS (basic) -1.10
EPS (diluted) -1.10
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 273,267
Short Ratio 3.40
Short % of Float n/a
Beta 7.07
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -6.25M
Net Income -6.04M
Free Cash Flow -5.36M
Net Cash -3.13M
Net Cash / Share -0.27
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -359.77%
ROE n/a
ROIC 149.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$2.00*
Low
2.00
Current: $0.0069
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2015201420132012201120102009200820072006
Revenue-0.060.030.010.450.431.33-0.060.09
Revenue Growth-107.68%439.17%-98.86%4.38%-67.83%---34.88%-
Gross Profit-0.060.030.010.450.431.33-0.06-
Operating Income-17.54-12.32-19.64-15.04-8.25-4.91-4.53-6.93-12.85-5.45
Net Income-22.20-14.96-19.07-12.33-10.03-4.15-10.96-10.60-13.23-5.34
Shares Outstanding11.2312.318.363.963.422.902.231.861.180.27
Earnings Per Share-1.98-1.24-2.33-3.12-4.89-1.50-6.10-5.70-11.20-19.70
Operating Cash Flow-5.08-10.72-19.41-10.29-6.93-3.63-2.27-3.94-2.54-4.93
Capital Expenditures0.07-0.04-0.25-1.49-0.32-0.01-0.02-0.03-0.02-0.11
Free Cash Flow-5.01-10.76-19.66-11.77-7.25-3.64-2.29-3.97-2.56-5.03
Cash & Equivalents0.291.338.374.169.271.621.180.251.200.58
Total Debt0.33--0.120.010.110.012.350.390.14
Net Cash / Debt-0.041.338.374.049.261.511.17-2.100.820.43
Assets0.8112.6023.0920.0219.5311.9111.3010.3111.290.81
Liabilities3.333.073.729.792.563.214.273.711.220.34
Book Value-2.539.5219.3710.2316.978.707.036.6010.070.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Echo Therapeutics, Inc.
Country United States
Employees 19

Stock Information

Ticker Symbol ECTE
Stock Exchange US OTC
Sector Healthcare
Industry Medical Devices
Unique Identifier OTCMKTS: ECTE
IPO Date November 10, 1997

Description

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Company to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.